Promoter targeted small RNAs: stabilising viral reservoirs
Anthony D Kelleher
+ Author Affiliations
- Author Affiliations
St Vincent’s Centre for Applied Medical Research, Sydney, NSW, Australia
Kirby Institute, UNSW, NSW, Australia
Tel: +61 2 8382 4941
Fax: +61 2 8382 4967
Email: t.kelleher@amr.org.au
Microbiology Australia 35(2) 103-104 https://doi.org/10.1071/MA14033
Published: 16 April 2014
Abstract
The viral reservoir, a major barrier to curative therapy for HIV-1 infection, consists of viral DNA sequestered in long-lived resting CD4+ T cells and macrophages in diverse anatomical sites. Some of these sites are recognised parts of the immune system, such as lymph nodes. Others, such as the brain are not 1. Current anti retroviral therapy (ART) does not substantially impact upon this reservoir. Early intervention with ART limits the reservoir but does not result in its elimination2–5.
References
[1] Kelleher, A.D. and Zaunders, J.J. (2006) Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection. Curr. HIV/AIDS Rep. 3, 5–12.| Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection.Crossref | GoogleScholarGoogle Scholar | 16522253PubMed |
[2] Murray, J.M. et al. (2014) HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy. J. Virol. 88, 3516–3526.
| HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 24403590PubMed |
[3] Murray, J.M. et al. (2012) Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 26, 543–550.
| Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xjs1Wqs7k%3D&md5=44de74043705c1ccd6a000c963eea56aCAS | 22410637PubMed |
[4] Koelsch, K.K. et al. (2011) Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 25, 2069–2078.
| Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXhtlGltrjM&md5=e3cd80bd92b239aa3c1340705d15695eCAS | 21860347PubMed |
[5] The SPARTAC Trial Investigators (2013) Short-course antiretroviral therapy in primary HIV infection. N. Engl. J. Med. 368, 207–217.
| Short-course antiretroviral therapy in primary HIV infection.Crossref | GoogleScholarGoogle Scholar | 23323897PubMed |
[6] Van Lint, C. et al. (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112–1120.
| 1:CAS:528:DyaK28XhvFGqsbs%3D&md5=491708c672b516a3d2339ecb2af5e21cCAS | 8605881PubMed |
[7] du Chene, I. et al. (2007) Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 26, 424–435.
| Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXotFKntA%3D%3D&md5=8b86451d33d0df179bf099f3874aca41CAS | 17245432PubMed |
[8] van Praag, R.M. et al. (2001) OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J. Clin. Immunol. 21, 218–226.
| OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3MXkvVSgurs%3D&md5=d70375975aca1cad520145a6c6e9d70bCAS | 11403229PubMed |
[9] Levy, Y. et al. (2009) Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 119, 997–1007.
| 1:CAS:528:DC%2BD1MXktlSntLw%3D&md5=8ee3fada35b0e268b46ba72ba8a1bac9CAS | 19287090PubMed |
[10] Routy, J. et al. (2012) Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 13, 291–296.
| Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xht1WlurbK&md5=55bbcd875a792084582b0f5745ac66d4CAS | 22276680PubMed |
[11] Archin, N.M. et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485.
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtFWjtrfP&md5=3232ff25692c00851930a16274cebb9eCAS | 22837004PubMed |
[12] Beliakova-Bethell, N. et al. (2013) Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS 27, 29–37.
| Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhvVWhtr3O&md5=9e809190ef6fc9dc0414faa5fa89bbc3CAS | 23221426PubMed |
[13] Suzuki, K. and Kelleher, A.D. (2010) Lessons from viral latency in T cells: manipulating HIV‐1 transcription by siRNA. Future Medicine 4, 199–213.
| 1:CAS:528:DC%2BC3cXjtVOru70%3D&md5=3b2faec89da07aef31d26a3cd7d60c6eCAS |
[14] Suzuki, K. et al. (2005) Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing 1, 66–78.
| 1:CAS:528:DC%2BD2MXhtF2lurfN&md5=896a494364f1e68022985c3abb40d7ddCAS | 19771207PubMed |
[15] Morris, K.V. et al. (2005) Inhibition of HIV-1 replication by siRNA targeting conserved regions of gag/pol. RNA Biol. 2, 17–20.
| Inhibition of HIV-1 replication by siRNA targeting conserved regions of gag/pol.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXhtFSrsLvP&md5=a0d41488cae3f89df41a0256aaf692baCAS | 17132935PubMed |
[16] Singh, A. et al. (2014) Long-term suppression of HIV-1C virus production in human peripheral blood mononuclear cells by LTR heterochromatization with a short double-stranded RNA. J. Antimicrob. Chemother. 69, 404–415.
| Long-term suppression of HIV-1C virus production in human peripheral blood mononuclear cells by LTR heterochromatization with a short double-stranded RNA.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXlvFOrsw%3D%3D&md5=12a10b3fe63ffd333901d728485c8d7cCAS | 24022068PubMed |
[17] Suzuki, K. et al. (2008) Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region. J. Biol. Chem. 283, 23353–23363.
| Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXpvFGgtrw%3D&md5=cfa31d74615cccd5def7822ba65a1102CAS | 18519571PubMed |
[18] Yamagishi, M. et al. (2009) Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. Microbes Infect. 11, 500–508.
| Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXkslyrsr8%3D&md5=c1520430e911740c9a6bda7b83e3b610CAS | 19233310PubMed |
[19] Suzuki, K. et al. (2011) Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biol. 8, 1035–1046.
| Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XkslCjt7o%3D&md5=f224061820bd7eed814427134c4504a1CAS | 21955498PubMed |
[20] Weinberg, M.S. et al. (2006) The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA 12, 256–262.
| The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XhtlSjs74%3D&md5=f43c6a0408d09f8700c805326ef17c5aCAS | 16373483PubMed |
[21] Ahlenstiel, C.L. et al. (2012) Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells. Nucleic Acids Res. 40, 1579–1595.
| Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XjtlGktrY%3D&md5=43f25d44a886afc8f4d3e90279fee199CAS | 22064859PubMed |
[22] Suzuki, K. et al. (2013) Promoter targeting shRNA suppresses HIV-1 infection in vivo through transcriptional gene silencing. Molecular Therapy – Nucleic Acids 2, e137.
| Promoter targeting shRNA suppresses HIV-1 infection in vivo through transcriptional gene silencing.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXkvVKiu7k%3D&md5=bd362f70f47adaf5bd67a830683dccc7CAS | 24301868PubMed |
